At a $270M market cap with no P/E, no Forward P/E, and an Altman Z-Score of -4.9, this is not a growth stock — it is a balance sheet distress story. The absence of earnings, negative EPS of -0.3, and projected EPS of -$1.39 next year eliminate any valuation support from profitability, while a Price/Sales of 12 and Price/Book of 8.8 are egregious for a company generating a -466.30% operating margin. A Piotroski F-Score of 1 signals fundamental deterioration across nearly every accounting dimension. The market is not mispricing this — it is heavily discounting insolvency risk and capital destruction. This is a speculative binary biotech equity, not a GARP opportunity.
